image credit: Adobe Stock

Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children

March 15, 2023


With this latest approval, children aged six months to four years who have completed their primary series with three doses of the companies’ original vaccine will be able to receive a 3µg booster dose of the bivalent vaccine after at least two months.

The vaccine is already authorised as the third dose of the three-dose primary series in this age group, but a booster dose is not authorised for these children at this time.

Read More on PMLiVE